Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: The EURODIAB prospective complications study

European Journal of Endocrinology

Volumn 166, Issue 2, 2012, Pages 325-332

  Nin, Johanna W M ^a,b,c   Ferreira, Isabel ^a,b,c   Schalkwijk, Casper G ^b,c   Prins, Martin H ^a,c   Chaturvedi, Nish ^d   Fuller, John H ^e   Stehouwer, Coen D A ^b,c   Karamanos, B ^f   Sjolie, A K ^f   Toeller, M ^f   Pozza, G ^f   Ferriss, B ^f   Porta, M ^f   Rottiers, R ^f   Michel, G ^f  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULSE PRESSURE; RETINOPATHY; RISK FACTOR;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; GLOMERULAR FILTRATION RATE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84856078195     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0662     Document Type: Article

References (42)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813-820. (doi:10.1038/414813a)
2. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH & Stehouwer CD. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009 52 705-714. (doi:10.1007/s00125-009-1263-5)
3. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P & Stehouwer CD. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010 59 2027-2032. (doi:10.2337/db09-1509)
4. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P & Stehouwer CD. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011 34 442-447. (doi:10.2337/dc10-1087)
5. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D & Schmidt AM. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. Journal of Biological Chemistry 1995 270 25752-25761. (doi:10.1074/jbc.270.43.25752)
6. Bianchi ME & Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Current Opinion in Genetics and Development 2005 15 496-506. (doi:10.1016/j.gde.2005.08.007)
7. Scaffidi P, Misteli T & Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002 418 191-195. (doi:10.1038/nature00858)
8. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ & Wang H. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. Journal of Immunology 2003 170 3890-3897.
9. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ & Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Molecular Medicine 2003 9 37-45.
10. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH & Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 2652-2660. (doi:10.1182/blood- 2002-05-1300)
11. Straino S, Di Carlo A, Mangoni A, De Mori R, Guerra L, Maurelli R, Panacchia L, Di Giacomo F, Palumbo R, Di Campli C, Uccioli L, Biglioli P, Bianchi ME, Capogrossi MC & Germani A. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. Journal of Investigative Dermatology 2008 128 1545-1553. (doi:10.1038/sj.jid.5701212)
12. Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V, Stigliano E, Pecorini G, Egashira K, De Angelis G, Ghirlanda G & Flex A. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010 59 1496-1505. (doi:10.2337/db09-1507)
13. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, Zeiher AM, Chavakis T & Dimmeler S. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circulation Research 2007 100 204-212. (doi:10.1161/01.RES.0000257774.55970.f4)
14. De Mori R, Straino S, Di Carlo A, Mangoni A, Pompilio G, Palumbo R, Bianchi ME, Capogrossi MC & Germani A. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2377-2383. (doi:10.1161/ATVBAHA.107. 153429)
15. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ & van der Poll T. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products (Rage) in Hmgb1 induced inflammation in vivo. Shock 2009 31 280-284. (doi:10.1097/SHK. 0b013e318186262d)
16. Li W, Sama AE & Wang H. Role of HMGB1 in cardiovascular diseases. Current Opinion in Pharmacology 2006 6 130-135. (doi:10.1016/j.coph.2005.10.010)
17. Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z, Cui B &Wen H. Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clinica Chimica Acta 2009 406 139-142. (doi:10.1016/j.cca.2009.06.016)
18. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ & Shen WF. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009 205 544-548. (doi:10.1016/j.atherosclerosis.2008.12.016)
19. Wang LJ, Lu L, Zhang FR, Chen QJ, De Catherina R & Shen WF. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. European Journal of Heart Failure 2011 13 440-449. (doi:10.1093/eurjhf/ hfq231)
20. Rivero A, Mora C, Muros M, Garcia J, Herrera H & Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clinical Science 2009 116 479-492. (doi:10.1042/CS20080394)
21. Kim J, Sohn E, Kim CS, Jo K & Kim JS. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. American Journal of Nephrology 2011 33 524-529. (doi:10.1159/000327992)
22. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE & Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney International 2001 60 219-227. (doi:10.1046/j.1523-1755.2001. 00789.x)
23. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M & Kohner EM. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001 24 284-289. (doi:10.2337/diacare.24.2.284)
24. Group TEICS. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994 37 278-285. (doi:10.1007/BF00398055)
25. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH & Stehouwer CD. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003 26 2165-2173. (doi:10.2337/diacare.26.7.2165)
26. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH & Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 2005 48 370-378. (doi:10.1007/s00125-004-1628-8)
27. Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH & Stehouwer CD. Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2002 25 2320-2327. (doi:10.2337/diacare.25.12.2320)
28. Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, Stehouwer CD, Witte DR, Fuller JH & Perin PC. Serum heat shock protein 27 and diabetes complications in the EURODIAB Prospective Complications Study: a novel circulating marker for diabetic neuropathy. Diabetes 2008 57 1966-1970. (doi:10.2337/db08-0009)
29. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH & Stehouwer CD. Adiponectin is inversely associated with renal function in type 1 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2006 91 129-135. (doi:10.1210/jc.2005-1117)
30. Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N & Stehouwer CD. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 2005 46 232-237. (doi:10.1161/01.HYP.0000164574.60279.ba)
31. Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH & Stehouwer CD. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. Journal of Internal Medicine 2005 258 450-459. (doi:10.1111/j.1365-2796.2005. 01560.x)
32. Schram MT, Chaturvedi N, Fuller JH & Stehouwer CD. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. Journal of Hypertension 2003 21 2035-2044. (doi:10.1097/00004872-200311000-00012)
33. Stehouwer CD, Henry RM & Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008 51 527-539. (doi:10.1007/s00125-007-0918-3)
34. Fossati P & Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical Chemistry 1982 28 2077-2080.
35. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31-41. (doi:10.1159/000180580)
36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N & Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine 1999 130 461-470.
37. Aldington SJ, Kohner EM, Meuer S, Klein R & Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 1995 38 437-444. (doi:10.1007/BF00410281)
38. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J & Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996 19 689-697. (doi:10.2337/diacare.19.7.689)
39. Li F, Yang N, Zhang L, Tan H, Huang B, Liang Y, Chen M & Yu X. Increased expression of toll-like receptor 2 in rat diabetic nephropathy. American Journal of Nephrology 2010 32 179-186. (doi:10.1159/000317023)
40. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D & Schmidt AM. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. Journal of Biological Chemistry 1999 274 31740-31749. (doi:10.1074/jbc.274.44.31740)
41. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S & Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. Journal of Biological Chemistry 2001 276 3195-3202. (doi:10.1074/jbc.M006545200)
42. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D & Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97 889-901. (doi:10.1016/S0092-8674(00)80801-6)